Study summary · research use only
Targeting negative energy balance with calorie restriction and mitochondrial uncoupling in db/db mice
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
In male db/db mice, a model of severe hyperglycemia, obesity, hypertriglyceridemia, and fatty liver, the authors compared approximately 50% calorie restriction with the mitochondrial uncoupler BAM15 (0.1% or 0.2% w/w in diet), including 0.2% BAM15 with time-restricted feeding, over 4 weeks, assessing body weight, glucose tolerance, and liver steatosis. Calorie restriction and high-dose 0.2% BAM15 decreased body weight similarly, but BAM15-treated mice showed greater glucose control improvement, with high-dose BAM15 normalizing fasting glucose and glucose tolerance to levels similar to lean db/+ controls; low-dose 0.1% BAM15 did not affect body mass but partially improved glucose tolerance. Combining high-dose BAM15 with time-restricted feeding produced the metabolic phenotype most similar to lean controls, associated with decreased glucagon levels and decreased hepatic gluconeogenesis enzyme expression.
Abstract
Calorie restriction is a first-line treatment for overweight individuals with metabolic impairments. However, few patients can adhere to long-term calorie restriction. An alternative approach to calorie restriction that also causes negative energy balance is mitochondrial uncoupling, which decreases the amount of energy that can be extracted from food. Herein we compare the metabolic effects of calorie restriction with the mitochondrial uncoupler BAM15 in the db/db mouse model of severe hyperglycemia, obesity, hypertriglyceridemia, and fatty liver. Male db/db mice were treated with ∼50% calorie restriction, BAM15 at two doses of 0.1% and 0.2% (w/w) admixed in diet, or 0.2% BAM15 with time-restricted feeding from 5 weeks of age. Mice were metabolically phenotyped over 4 weeks with assessment of key readouts including body weight, glucose tolerance, and liver steatosis. At termination, liver tissues were analysed by metabolomics and qPCR. Calorie restriction and high-dose 0.2% BAM15 decreased body weight to a similar extent, but mice treated with BAM15 had far better improvement in glucose control. High-dose BAM15 treatment completely normalized fasting glucose and glucose tolerance to levels similar to lean db/+ control mice. Low-dose 0.1% BAM15 did not affect body mass but partially improved glucose tolerance to a similar degree as 50% calorie restriction. Both calorie restriction and high-dose BAM15 significantly improved hyperglucagonemia and liver and serum triglyceride levels. Combining high-dose BAM15 with time-restricted feeding to match the time that calorie restricted mice were fed resulted in the best metabolic phenotype most similar to lean db/+ controls. BAM15-mediated improvements in glucose control were associated with decreased glucagon levels and decreased expression of enzymes involved in hepatic gluconeogenesis. BAM15 and calorie restriction treatments improved most metabolic disease phenotypes in db/db mice. However, mice fed BAM15 had superior effects on glucose control compared to the calorie restricted group that consumed half as much food. Submaximal dosing with BAM15 demonstrated that its beneficial effects on glucose control are independent of weight loss. These data highlight the potential for mitochondrial uncoupler pharmacotherapies in the treatment of metabolic disease.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.